DocMorris AG: Daniel Wüest becomes new CFO at DocMorris

DocMorris AG / Key word(s): Personnel
DocMorris AG: Daniel Wüest becomes new CFO at DocMorris

08-May-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Frauenfeld, 8 May 2024

Press release
Ad hoc announcement pursuant to Art. 53 LR

Daniel Wüest becomes new CFO at DocMorris

The Board of Directors of DocMorris AG has appointed Daniel Wüest to succeed
Marcel Ziwica as CFO. Daniel Wüest will take over his new role on 1 October
2024.

Marcel Ziwica (49) will leave the company at his own request at the end of
the year in order to reorient himself professionally after 23 years. Walter
Oberhänsli, Chairman of the Board of Directors, commented: 'We would like to
express our sincere thanks to Marcel Ziwica. With him, a man from the very
beginning is leaving the company, who has played a key role in all major
projects of the last two decades and who has decidedly shaped the
development of DocMorris. The company owes him a lot, both professionally
and personally. We wish him all the best for his new start. With Daniel
Wüest, DocMorris has been able to gain a competent successor and proven
financial expert for this important position.'

The Swiss economist Daniel Wüest (54) has spent the last five years as Group
CFO of the listed building supplier Arbonia, where he was actively involved
in the strategic and financial realignment of the Group through acquisitions
and disposals. Prior to that, Daniel Wüest worked for UBS for more than
twenty years in various investment banking positions, where he advised on
numerous mergers, acquisitions, debt and equity financings, and IPOs.

CEO Walter Hess is pleased about the new member of the Executive Board:
'Daniel Wüest is a proven expert in corporate finance. His broad background
of experience in the international corporate environment as well as in
financial management and capital markets is extremely valuable to us. I am
very much looking forward to working with him. I would like to express my
sincere thanks to Marcel Ziwica for his excellent contribution, which is
characterised by mutual respect and appreciation, which we will continue
until his departure.'

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

     20 August 2024     2024 Half-year results (conference call/webcast)
     15 October 2024    Q3/2024 Trading update

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online
pharmacy, marketplace and professional healthcare with strong brands in
Germany and other European countries. Deliveries are mainly from the highly
automated logistics centre in Heerlen, the Netherlands, with a capacity of
over 27 million parcels per year. In Spain and France, the company operates
the leading marketplace for health and personal care products in Southern
Europe. With its business model, DocMorris offers its patients, customers
and partners a broad range of products and services. In doing so, DocMorris
is pursuing its vision of creating a digital health ecosystem for everyone
to manage their health in one click. The company was renamed from Zur Rose
Group AG to DocMorris AG in May 2023 after the Swiss business was sold to
Migros/Medbase. Excluding the Swiss business, about 1,600 employees in
Germany, the Netherlands, Spain, France and Switzerland generated an
external revenue of CHF 1,038 million serving over 9 million active
customers in 2023. The shares of DocMorris AG are listed on the SIX Swiss
Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For
further information, please visit corporate.docmorris.com.


---------------------------------------------------------------------------

End of Inside Information

---------------------------------------------------------------------------

   Language:       English
   Company:        DocMorris AG
                   Walzmühlestrasse 49
                   8500 Frauenfeld
                   Switzerland
   ISIN:           CH0042615283
   Listed:         SIX Swiss Exchange
   EQS News ID:    1897901

End of Announcement EQS News Service
---------------------------------------------------------------------------

1897901 08-May-2024 CET/CEST